iron deficiency anaemia
Other · 2013–2018
No submission for this condition has carried consumer input, including the 3 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ferric derisomaltose Treatment of iron deficiency anaemia when treatment with oral iron is ineffective or not tolerated. | Jul 2018 | Recommended | none received |
| ferric carboxymaltose Treatment of iron deficiency anaemia (IDA). | Nov 2018 | Recommended | no section in document |
| iron sucrose Iron deficiency anaemia in patients undergoing chronic haemodialysis and receiving supplemental erythropoietin therapy. | Nov 2014 | Recommended with restriction | none received |
| ferric carboxymaltose Treatment of iron deficiency anaemia where oral iron preparations are not tolerated, ineffective or otherwise inappropriate. | Mar 2013 | Recommended | unclear |
| ferric carboxymaltose Iron deficiency anaemia (IDA) when oral iron preparations are ineffective or cannot be used. | Nov 2013 | Recommended | unclear |
What the PBS pays
$173M in government benefit over 2024–25, across 639,323 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ferric carboxymaltose | $157.6M |
| ferric derisomaltose | $14.9M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| ironCARBOFERM iron (as ferric carboxymaltose) 100 mg/2 mL solution for inj | 2002 | 30 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.